Facilitated By

San Antonio Medical Foundation

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Bhavaraju-Sanka, Ratna K.
Funded by
PTC THERAPEUTICS INC.
Research Start Date
Status
Active
Collaborative Project
Clinical Care
Drug Discovery
Other